Program
Tretinoin Gel Microsphere, 0.04%
Also written as “Tretinoin Gel Microsphere, 0.1%”.
Its studies are mostly in Acne Vulgaris, led by Sun Pharmaceutical Industries.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | 20 open or running | phase 1since Mar 9, 2026 | May 7, 2021 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 7, 2021First study: early phase 1 study in Acne VulgarisFirst studyNCT04883736 · 973 enrolled · United States
- Mar 9, 2026Phase 1 study in Acne VulgarisNCT07469228 · 1,043 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07469228Acne Vulgaris · United States | 1 | Completed | Dec 15, 2025 | 1,043 |
| NCT04883736Acne Vulgaris · United States | Early 1 | Completed | Apr 16, 2021 | 973 |
How it is read
Names in the registry
- “Tretinoin Gel Microsphere, 0.04%”, 1 entry
- “Tretinoin Gel Microsphere, 0.1%”, 1 entry
Conditions, from the studies’ own filings
- Acne Vulgaris, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.